Abstract
A cholera-vaccine field trial in a rural area of East Pakistan where cholera is highly endemic has indicated that a high-potency whole-cell vaccine can provide significant protection against disease due to Vibrio cholerae for at least 18 months. This vaccine gave more than 70% protection during the first cholera season after vaccination. In the second cholera season after the administration of a single dose of vaccine, protection fell in those under 5 years of age, while continuing at significantly effective levels in older persons.
Purified Ogawa antigen (lipopolysaccharide) afforded significant protection to adults against disease due to the heterologous Inaba serotype, but only protected children against milder diarrhoeas.
The effect of cholera vaccine on the incidence of infections among family contacts of cholera patients was variable. Vaccine had no effect on the proportion of asymptomatic infections.
Diarrhoeal disease associated with V. cholerae occurred predominantly among children, while protection was most marked among adults. Adverse reactions were practically restricted to the adults, suggesting that children will not only tolerate a larger dose, but actually require a larger dose for maximum protection against infection.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Benenson A. S., Joseph P. R., Oseasohn R. O. Cholera vaccine field trials in east Pakistan. 1. Reaction and antigenicity studies. Bull World Health Organ. 1968;38(3):347–357. [PMC free article] [PubMed] [Google Scholar]
- Das Gupta A., Sinha R., Shrivastava D. L., De S. P., Taneja B. L., Rao M. S., Abou-Gareeb A. H. Controlled field trial of the effectiveness of cholera and cholera El Tor vaccines in Calcutta. Bull World Health Organ. 1967;37(3):371–385. [PMC free article] [PubMed] [Google Scholar]
- FEELEY J. C. CLASSIFICATION OF VIBRIO CHOLERAE (VIBRIO COMMA), INCLUDING EL TOR VIBRIOS, BY INFRASUBSPECIFIC CHARACTERISTICS. J Bacteriol. 1965 Mar;89:665–670. doi: 10.1128/jb.89.3.665-670.1965. [DOI] [PMC free article] [PubMed] [Google Scholar]
- FEELEY J. C., PITTMAN M. LABORATORY ASSAYS OF CHOLERA VACCINE USED IN FIELD TRIAL IN EAST PAKISTAN, 1963. Lancet. 1965 Feb 27;1(7383):449–450. doi: 10.1016/s0140-6736(65)91585-0. [DOI] [PubMed] [Google Scholar]
- Gordon R. S., Jr, Feeley J. C., Greenough W. B., 3rd, Sprinz H., Oseasohn R. Cholera: combined clinical staff conference at the National Institutes of Health. Ann Intern Med. 1966 Jun;64(6):1328–1351. doi: 10.7326/0003-4819-64-6-1328. [DOI] [PubMed] [Google Scholar]
- Mosley W. H., Benenson A. S., Barui R. A serological survey for cholear antibodies in rural east Pakistan. 1. The distribution of antibody in the control population of a cholera-vaccine field-trial area and the relation of antibody titre to the pattern of endemic cholera. Bull World Health Organ. 1968;38(3):327–334. [PMC free article] [PubMed] [Google Scholar]
- Mosley W. H., Benenson A. S., Barui R. A serological survey for cholera antibodies in rural east Pakistan. 2. A comparison of antibody titres in the innunized and control populationd of a cholera-vaccine field-trial area and the relation of antibody titre to cholera case rate. Bull World Health Organ. 1968;38(3):335–346. [PMC free article] [PubMed] [Google Scholar]
- Mukerjee S., Basu S., Bhattacharya P. A new trend in cholera epidemiology. Br Med J. 1965 Oct 9;2(5466):837–839. doi: 10.1136/bmj.2.5466.837. [DOI] [PMC free article] [PubMed] [Google Scholar]
- OSEASOHN R. O., BENENSON A. S., FAHIMUDDIN M. FIELD TRIAL OF CHOLERA VACCINE IN RURAL EAST PAKISTAN. FIRST YEAR OF OBSERVATION. Lancet. 1965 Feb 27;1(7383):450–452. doi: 10.1016/s0140-6736(65)91586-2. [DOI] [PubMed] [Google Scholar]
- Watanabe Y., Verwey W. F. Protective antigens from El Tor vibrios. 1. The preparation and properties of a purified protective antigen from an El Tor vibrio (Ogawa subtype). Bull World Health Organ. 1965;32(6):809–821. [PMC free article] [PubMed] [Google Scholar]